Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Molson Coors shares fizzle after earnings amid down-day for stocks

Molson Coors shares fizzle after earnings amid down-day for stocksMolson Coors Brewing Company (NYSE:TAP) – Shares in the beer brewing company are on the decline today, joining the broad-based sell-off in equities as investors re-focus attention on the debt crisis in Europe and looming fiscal cliff in the U.S. with the conclusion of Tuesday’s Presidential election. Molson Coors shares are down roughly 4% as of 12:10 p.m. ET to stand at $41.48 after the company reported better-than-expected third-quarter profits, but missed revenue estimates, ahead of the opening bell this morning. One or more options traders appear to be bracing for further declines in the price of the underlying shares during the five months. It looks like strategists purchased more than 1,000 puts at the April 2013 $40 strike for an average premium of $1.90 per contract. The bearish puts may be profitable at expiration if TAP’s shares drop more than 8% from the current level to breach the average breakeven price of $38.10 at expiration next year. Shares in Molson Coors Brewing Co. last traded below $38.10 in June.

Pfizer Inc. (NYSE:PFE) – Pharmaceuticals giant, Pfizer, Inc., is trading well off its lowest level of the session at present, down 0.95% at $24.26 as of 12:40 p.m. ET after earlier sliding as much as 2% to an intraday low of $23.99 on Wednesday morning. Heavy trading traffic in weekly options with two full trading sessions remaining to expiration indicates short-term bets on the stock are looking for shares to move. The bulk of the volume is in weekly calls looking for a quick rebound in the price of the underlying, though buyers did generate some traffic in the weekly puts as well. Weekly options volume is greatest in the Nov. 09 ’12 $25 strike call where upwards of 9,700 lots changed hands against open interest of 6,548 contracts. Most of the calls in play this morning appear to have been purchased for an average premium of $0.08 apiece. Buyers of these upside calls stand ready to profit at expiration this week as long as Pfizer’s shares settle above the breakeven price of $25.08. The lower Nov. 09 ’12 $24.5 strike call traded 4,750 times by 12:45 p.m. ET against open interest of 1,522 contracts. These call options were also mostly purchased, with traders shelling out an average premium of $0.11 per contract earlier in the trading day. Short-term bearish bets were established at the Nov. 09 ’12 $24.5 and $25 strikes, with upwards of 2,000 contracts in play at each strike in the first half of the session.

Ciena Corporation (NASDAQ:CIEN) – Plans announced by AT&T this morning to spend $14 billion on network expansion over the next three years sparked heavier-than-usual trading traffic in Ciena Corp. options this morning and drove shares in the name up as much as 12.75% to $14.86 in the first half of the session. The provider of networking products and services appears to have attracted buyers of downside puts, perhaps as some strategists seek to lock in the sharp rally in the price of the underlying today. The most active options by volume on CIEN are the Dec. $14 strike puts, which have changed hands more than 3,500 times against open interest of just 222 contracts. It looks like most of the volume was purchased for an average premium of $0.94 apiece in the early going, thus protecting buyers to the downside in the event shares drop 12% off today’s high of $14.86 and breach the average breakeven price of $13.06 by expiration next month. Ciena Corp. is scheduled to report fourth-quarter earnings in the first week of December.

Caitlin Duffy

Equity Options Analyst

The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither Interactive Brokers LLC nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither IB nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance is not necessarily indicative of future results.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.